{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:45:48Z","timestamp":1787838348054,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,20]]},"DOI":"10.1097\/cm9.0000000000002860","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:00:09Z","timestamp":1700622009000},"page":"473-475","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of interleukin-17 inhibitors on radiographic progression in psoriatic arthritis: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"137","author":[{"given":"Han-Lei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Ming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"R1-20250602","first-page":"1439","article-title":"Prevalence of psoriatic arthritis in Chinese population with psoriasis: A multicenter study conducted by experienced rheumatologists","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin Med J"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-020-2103-8","article-title":"Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research","volume":"22","author":"van der Heijde","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"e000723","DOI":"10.1136\/rmdopen-2018-000723","article-title":"Secukinumab in the treatment of psoriatic arthritis: Efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: A two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"e001600","DOI":"10.1136\/rmdopen-2021-001600","article-title":"Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study","volume":"7","author":"Mease","year":"2021","journal-title":"RMD Open"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"van der Heijde","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/rheumatology\/key297","article-title":"Trajectory of radiographic change over a decade: The effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis","volume":"58","author":"Allard","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20250602","first-page":"469","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort","volume":"35","author":"Chandran","year":"2008","journal-title":"J Rheumatol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:03:24Z","timestamp":1748891004000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002860","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"2023-03-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}